Myeloid disease experts take on the immune system error

Hear expert perspectives on myeloid diseases, current treatment limitations, and TIM-3 as a novel target

Uma Borate, MBBS

HEMATOLOGY SPECIALIST AND ASSOCIATE PROFESSOR

The Ohio State University Comprehensive Cancer Center—James, United States

Patient Risk Stratification

Dr Borate describes MDS patient risk stratification as defined by IPSS-R and discusses using a patient’s risk category to determine appropriate treatment.

Uwe Platzbecker, MD, PhD

DIRECTOR OF MEDICAL CLINIC I

Hematology and Cell Therapy University Hospital in Leipzig, Germany

Novel Target TIM-3

Dr Platzbecker describes the role of TIM-3 as a novel target and how it relates to higher-risk MDS.

David Steensma, MD

GLOBAL HEMATOLOGY HEAD Transitional Clinical Oncology

Novartis Institutes for BioMedical Research (NIBR), United States

Immune Dysfunction

Dr Steensma discusses disease complexity in MDS, particularly immune dysfunction, and how it manifests differently depending on the severity of MDS.

Andrew Wei, MBBS, PhD

CANCER AGENCY RESEARCH FELLOW AND HEMATOLOGIST

Alfred Hospital at Monash University, Australia

Unmet Needs

Dr Wei reviews unmet needs in higher-risk MDS, including poor prognosis and limited treatment options.

 

This is a global website and is intended for health care professionals. The information on this site is intended for educational purposes only and is not country-specific.

 

Use of website is governed by the Terms of Use and Privacy Policy.

Copyright © 2021 Novartis AG. All rights reserved.

6/21 112789-1